A study testing whether a new weekly shot from Johns Hopkins University, tirzepatide, can help with weight.

Who can join
Adults 18+, have obesity or are overweight, BMI 27+.
What you take
tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.3 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 2Sponsor Johns Hopkins UniversityDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 105

What this study is for

Primary condition: Obesity and Overweight. Also studied in: Binge Eating Disorder.

Full scientific study title: Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have a BMI >=30 kg/m2 or >=27 kg/m2
  • previously diagnosed with at least one obesity-related comorbidity:
  • Have at least one self-reported unsuccessful dietary effort to lose body weight
  • Meet Diagnostic and Statistical Manual (DSM)-5 criteria for Binge Eating Disorder (BED) as diagnosed by the Eating Disorder Examination interview and confirmed by binge-eating diaries that is moderate or greater in severity (4 or more episodes per week)
  • Are 18 years of age or older

Key exclusion criteria

  • Current diagnosis of bulimia nervosa or anorexia nervosa
  • Have type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma
  • Have laboratory evidence diagnostic of diabetes mellitus during screening, including an HbA1c >=6.5% or fasting glucose >126 mg/dL
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening
  • Have a prior or planned surgical treatment for obesity (excluding lap-band if removed >6 months prior to screening or liposuction or abdominoplasty if performed >1 year prior to screening)

Where this study is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Maryland1 site
  • Johns Hopkins University
    Baltimore, Maryland
    Clinical Research Coordinator667-306-9366abisson2@jh.edu

Timeline

Started enrolling: 2025-09-17. Expected completion: 2027-12-01. Last updated on ClinicalTrials.gov: 2025-09-22.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.